Khodzhakuliev B G, Naumov V G, Blinov S I, Grigor'iants R A
Kardiologiia. 1992 Apr;32(4):41-4.
The antiarrhythmic effects of allapinine were studied in 57 patients with chronic circulatory failure (CCF) and cardiac arrhythmias by employing 48-hour Holter monitoring. Allapinine was found to suppress premature ventricular contraction, group premature ventricular contraction and 'runs' of ventricular tachycardia by 82.5, 88.6, and 93.1%, respectively. The antiarrhythmic activity of the agent was more pronounced in patients with coronary heart disease, Stages I-IIA CCF and left ventricular ejection fraction greater than 40%. In addition, in Stages I-IIA CCF allapinine increased myocardial contractility and left ventricular ejection fraction, whereas in Stages IIB-III CCF it showed a slight cardiodepressive effect. Thus, when given in the course therapy in patients with CCF, allapinine has a high antiarrhythmic activity and, to a lesser extent, affects central hemodynamics.
采用48小时动态心电图监测，对57例慢性循环衰竭（CCF）合并心律失常患者研究了阿拉平宁的抗心律失常作用。结果发现，阿拉平宁可使室性早搏、成组室性早搏及室性心动过速“连发”分别减少82.5%、88.6%和93.1%。该药的抗心律失常活性在冠心病、Ⅰ - ⅡA期CCF及左心室射血分数大于40%的患者中更为显著。此外，在Ⅰ - ⅡA期CCF患者中，阿拉平宁可增强心肌收缩力及左心室射血分数，而在ⅡB - Ⅲ期CCF患者中则显示出轻微的心脏抑制作用。因此，在CCF患者的疗程治疗中应用阿拉平宁时，它具有较高的抗心律失常活性，且对中心血流动力学的影响较小。
